Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer
Bioorganic Chemistry · 2026-11 · 183 · 110601
DOI: 10.1016/j.bioorg.2026.110601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Lei Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, and State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Science and Technology Program of Gansu Province, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
KRAS G12C mutation is a key driver of multiple solid tumors, and has recently become a crucial target for therapy via small molecules that covalently bind to the mutated cysteine. Herein, a series of benzisothiazole derivatives is presented as KRAS G12C inhibitors utilizing a scaffold-hopping strategy. Among them, S32 exhibited remarkable antiproliferative efficacy, specifically in the NCI-H23 cell line (IC50 = 0.55 ± 0.05 μM). Docking studies of S32 revealed that the oxygen atom of the trifluoroethoxy group at the C-7 position of benzisothiazole formed a hydrogen bond with His95 and extended into a solvent-exposed region. Additionally, S32 obviously inhibited nucleotide exchange efficiency, stabilizing KRAS in the GDP-bound state and inhibited the downstream ERK/AKT signaling pathways of KRAS in NCI-H23 and NCI-H358 cells, while inducing apoptosis by upregulating BAX and downregulating BCL-2 apoptotic proteins. Furthermore, S32 achieved a tumor growth inhibition (TGI) of 90.8% at a dose of 30 mg/kg. These results confirmed that S32, with a benzisothiazole scaffold, was an effective KRAS G12C inhibitor, potentially promoting cancer therapy development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, and State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou 730000, China.
- School of Pharmacy, and State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou 730000, China. Electronic address: zhangjunmin@lzu.edu.cn.
- School of Pharmacy, and State Key Laboratory of Natural Product Chemistry, Lanzhou University, Lanzhou 730000, China. Electronic address: chenshw@lzu.edu.cn.
Förderung
- Science and Technology Program of Gansu Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Cheng, L., Hou, S. J., Nie, Q., Ge, F. Y., Wang, X. B., Wang, Y. R., Zhang, Y. S., Li, N., Zhang, J., & Chen, S. W. (2026). Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer. Bioorganic Chemistry, 183, 110601. https://doi.org/10.1016/j.bioorg.2026.110601
Vancouver
Cheng L, Hou SJ, Nie Q, Ge FY, Wang XB, Wang YR, et al. Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer. Bioorganic Chemistry. 2026;183:110601. doi:10.1016/j.bioorg.2026.110601
BibTeX
@article{Cheng2026,
author = {Cheng, Lei and Hou, Su-Juan and Nie, Qiuying and Ge, Feng-Ya and Wang, Xi-Bo and Wang, Yi-Ru and Zhang, Yao-Sheng and Li, Na and Zhang, Junmin and Chen, Shi-Wu},
title = {Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {183},
pages = {110601},
doi = {10.1016/j.bioorg.2026.110601}
}
EUVIMED